Oxford Genome Sciences announces new Therapeutic Antibody Deal with Medarex
New agreement to drive the development of OGeS' own pipeline of antibodies in cancer
Oxford Genome Sciences (UK) Ltd (OGeS) announced a second partnering agreement with Medarex, Inc. This new agreement provides OGeS with broad access to Medarex's fully human antibody technology and will potentially enable OGeS to accelerate the development of its own pipeline of novel fully human antibodies in the field of cancer.
Under the terms of the agreement, OGeS will license Medarex's proprietary transgenic mouse technology to generate antibody therapeutics against cancer targets that OGeS identifies using its unique OGAP® database. OGeS will retain full worldwide rights to the new human antibodies generated, and Medarex has the right to receive license fees, milestone payments and royalties on commercial sales of any products that may result from this agreement. Further financial details were not disclosed.
Medarex's technology offers the potential for drug developers to generate high affinity fully human antibodies. OGeS will be able to potentially build a valuable and broad therapeutic antibodies pipeline by combining Medarex's technology with its OGAP database, which enables the identification of best in class targets,
In parallel, to further accelerate its pipeline development, OGeS has established a three-way agreement with Biosite Incorporated and Medarex. Medarex will provide access to its transgenic technology to Biosite, and Biosite will carry out the early stage antibody generation on behalf of OGeS for a potentially large number of OGeS' antibody programs. This is partly in exchange for Biosite receiving access to the OGeS diagnostic targets in colorectal and ovarian cancer. This arrangement is expected to improve OGeS' productivity to put top quality antibody therapeutic programs into development more quickly.
In addition, under a separate agreement between OGeS and Biosite, Biosite can also establish a companion diagnostic assay on certain programs selected by Biosite and OGeS. This provides OGeS with the opportunity to create a significant portfolio of personalised cancer therapeutics with companion diagnostics for many of its oncology targets.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
